Statins enhance anti-tumor effect of suberoylanilide hydroxamic acid on human non-small cell lung carcinoma cells.
- Author:
Gui-kai LIANG
1
;
Zhang-ting YAO
1
;
Jie-qiong ZHANG
1
;
Xi CHEN
1
;
Rui-yang LIU
1
;
Hui-hui CHEN
1
;
Hong-hai WU
1
;
Lu JIN
2
;
Ling DING
1
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Apoptosis; Carcinoma, Non-Small-Cell Lung; pathology; Cell Line, Tumor; drug effects; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; metabolism; Humans; Hydroxamic Acids; pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors; pharmacology; Poly(ADP-ribose) Polymerases; metabolism
- From: Journal of Zhejiang University. Medical sciences 2015;44(5):500-505
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the anti-tumor effect of the combination of suberoylanilide hydroxamic acid(SAHA) with statins(lovastatin or simvastatin) on non-small cell lung carcinoma(NSCLC) cells.
METHODSHuman NSCLC A549 cells were treated with SAHA in combination of lovastatin or simvastatin. The cell growth was analyzed by SRB method, and the apoptosis of A549 cells was assessed by flow cytometer. The expression of cleaved poly-ADP-ribose polymerase(cleaved-PARP) and p21 protein was analyzed by Western-blotting when A549 cells were challenged with 2.5μmol/L SAHA and 5μmol/L lovastatin.
RESULTSLovastatin and simvastatin synergized SAHA in the inhibition of A549 cells. SAHA induced apoptosis was also enhanced by lovastatin. Treatment with 2.5μmol/L SAHA significantly up-regulated the expression of p21 protein in 48 h, while the protein expression was reduced in combined treatment with 5μmol/L lovastatin.
CONCLUSIONStatins can synergize the anti-tumor effect of SAHA in human NSCLC cells through a p21-dependent way.
